The long-term objective of this proposal is the prevention of autoimmune mediated Type 1 diabetes mellitus (T1D). Many promising interventions must be tested in a safe and efficient manner in order to achieve this goal. A well-organized cooperative network of capable institutes, Type 1 Diabetes TrialNet, has greatly facilitated the prompt completion of many clinical trials needed to test these potential interventions. The application responds to the RFA to select the clinical centers that will form TrialNet for the next 3 to 5 years. The first goal of this proposal is to both continue and improve the infrastructure essential to completing the current TrialNet studies seeking to prevent T1D in subjects at risk for T1D and to preserve endogenous insulin secretion in subjects with new onset T1D. This section of the proposal reviews Stanford's seven-year experience as a TrialNet national center in central California. The proposal highlights Stanford's plans for extending and improving recruitment and retention activities for the next 3 to 5 years. These plans include both completing the current TrialNet studies and implementing the expected upcoming trials. Stanford is particularly excited about the soon to start TrialNet protocol, developed by Stanford, to test the glucose sensor enhanced strict glycemic control in subjects with new onset T1D. The second goal proposes a clinical study to develop and test a novel intervention using modified autologous dendritic cell therapy to preserve endogenous insulin secretion in subjects with new onset T1D in a multicenter TrialNet study. The proposal, Transgenic IL-4 expression by autologous dendritic cells in new onset Type 1 diabetes (aDC/IL-4), articulates Stanford's approach to testing this therapy in a collaborative manner with other centers in TrialNet. Studies using dendritic cells therapeutically have demonstrated no significant adverse events, so that it is now reasonable to consider this innovative approach as a possible therapy for diabetes prevention. This proposal describes both Phase 1 safety studies followed by Phase 2 efficacy studies using aDC/IL-4. Ultimately, this therapy will likely have a role in preventing T1D

Public Health Relevance

Type 1 diabetes mellitus is a serious life limiting disease that strikes predominantly in children and adolescents. The TrialNet clinical research network, the focus of the proposal, is charged with designing and conducting studies aimed at preventing or delaying the onset or progression of type 1 diabetes, both highly relevant public health goals

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-R (O1))
Program Officer
Leschek, Ellen W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Schools of Medicine
United States
Zip Code
Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92
Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:
Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:
Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486
Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276
Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894
Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225
Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317

Showing the most recent 10 out of 75 publications